Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03833934 · OUTCOME

Treatment Outcome: >50% Reduction of ALK Fusion Allelle Frequency

Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance · Source last updated 2025-10-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
32 months

What was measured

New ALK TKI treatment resulted in \>50% reduction of ALK fusion allelle frequency

Analysis population: Patients who had additional optional blood draw following initiation of new ALK TKI therapy

Groups in this outcome

ALK-positive NSCLC With Progression

Patients in this group signed consent, met eligibility criteria, and all had ALK-positive cancer of a primary lung lesion with systemic progression (excluding the central nervous system)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
ALK-positive NSCLC With Progression14

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
ALK-positive NSCLC With Progression7Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        7
denoms
  1. counts
    1. group Id
      OG000
      value
      14
    units
    Participants
description
New ALK TKI treatment resulted in \>50% reduction of ALK fusion allelle frequency
groups
  1. description
    Patients in this group signed consent, met eligibility criteria, and all had ALK-positive cancer of a primary lung lesion with systemic progression (excluding the central nervous system)
    id
    OG000
    title
    ALK-positive NSCLC With Progression
param Type
COUNT_OF_PARTICIPANTS
population Description
Patients who had additional optional blood draw following initiation of new ALK TKI therapy
reporting Status
POSTED
time Frame
32 months
title
Treatment Outcome: >50% Reduction of ALK Fusion Allelle Frequency
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice